Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug trial for painful skin condition halted early

NCT ID NCT05905783

Disease control Sponsor: ACELYRIN Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called izokibep for people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps. The trial aimed to see if izokibep could reduce skin abscesses and inflammation. It included 258 adults who had not responded to other treatments. The study was terminated early, so final results are not available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

258 people

The number who actually took part.

Started

Jun 2023

Finished

Jan 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: General * Participant has provided signed informed consent including consenting to comply with the requirements and restrictions listed in the informed consent form (ICF) and in protocol * 18 years of age or older * No known history of active tuberculosis unless adequately treated according to World Health Organization/Center for Disease Control and Prevention therapeutic guidance and determined to be fully recovered by a tuberculosis specialist Type of Participant and Disease Characteristics * Diagnosis of HS for ≥ 6 months prior to first dose of study drug * Hidradenitis suppurativa lesions present in ≥ 2 distinct anatomic areas, one of which is Hurley Stage II or Hurley Stage III * A total AN count of ≥ 5 at screening and Day 1 prior to enrollment/randomization * Participant must have had an inadequate response to oral antibiotics OR exhibited recurrence after discontinuation to, OR demonstrated intolerance to, OR have a contraindication to oral antibiotics for treatment of their HS * Must agree to use daily or a minimum of 3 days a week over-the-counter topical antiseptics * Participant must be willing to complete a daily skin pain diary Exclusion Criteria: Medical Conditions * Draining fistula count of \> 20 * Outpatient surgery ≤ 8 weeks prior or inpatient surgery ≤ 12 weeks prior to enrollment/randomization * Other active skin disease or condition that could interfere with study assessments * History of active inflammatory bowel disease (IBD) OR symptoms within the last year that may be suggestive of IBD * Chronic pain not associated with HS * Uncontrolled, clinically significant system disease * History of demyelinating disease or neurological symptoms suggestive of demyelinating disease * Malignancy within 5 years * The participant is at risk of self-harm or harm to others * Active infection or history of certain infections * Tuberculosis or fungal infection seen on available chest x-ray taken within 3 months prior to first dose of study drug or at screening (Exception: documented evidence of completed treatment and clinically resolved) * Known history of human immunodeficiency virus (HIV) Other protocol defined Inclusion/Exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa

Contacts and locations

Locations

  • Clinical Research Site

    Birmingham, Alabama, 35233, United States

  • Clinical Research Site

    Scottsdale, Arizona, 85255, United States

  • Clinical Research Site

    Scottsdale, Arizona, 85260, United States

  • Clinical Research Site

    Fayetteville, Arkansas, 72703, United States

  • Clinical Research Site

    Encino, California, 91436, United States

  • Clinical Research Site

    Fountain Valley, California, 92708, United States

  • Clinical Research Site

    Fremont, California, 94538, United States

  • Clinical Research Site

    Los Angeles, California, 90045, United States

  • Clinical Research Site

    Santa Monica, California, 90404, United States

  • Clinical Research Site

    Boca Raton, Florida, 33486, United States

  • Clinical Research Site

    Brandon, Florida, 33511, United States

  • Clinical Research Site

    Coral Gables, Florida, 33134, United States

  • Clinical Research Site

    Hollywood, Florida, 33021, United States

  • Clinical Research Site

    Tampa, Florida, 33607, United States

  • Clinical Research Site

    Tampa, Florida, 33613, United States

  • Clinical Research Site

    Atlanta, Georgia, 30315, United States

  • Clinical Research Site

    Sandy Springs, Georgia, 30328, United States

  • Clinical Research Site

    Savannah, Georgia, 31419, United States

  • Clinical Research Site

    Springfield, Illinois, 62702, United States

  • Clinical Research Site

    Indianapolis, Indiana, 46250, United States

  • Clinical Research Site

    Plainfield, Indiana, 46168, United States

  • Clinical Research Site

    Topeka, Kansas, 66614, United States

  • Clinical Research Site

    Murray, Kentucky, 42071, United States

  • Clinical Research Site

    Baton Rouge, Louisiana, 70808, United States

  • Clinical Research Site

    Baton Rouge, Louisiana, 70809, United States

  • Clinical Research Site

    New Orleans, Louisiana, 70115, United States

  • Clinical Research Site

    Largo, Maryland, 20774, United States

  • Clinical Research Site

    Boston, Massachusetts, 02215, United States

  • Clinical Research Site

    Canton, Michigan, 48187, United States

  • Clinical Research Site

    Troy, Michigan, 48084, United States

  • Clinical Research Site

    Lebanon, New Hampshire, 03766, United States

  • Clinical Research Site

    New York, New York, 10128, United States

  • Clinical Research Site

    Charlotte, North Carolina, 28277, United States

  • Clinical Research Site

    Boardman, Ohio, 44512, United States

  • Clinical Research Site

    Mason, Ohio, 45040, United States

  • Clinical Research Site

    Springfield, Ohio, 45505, United States

  • Clinical Research Site

    Portland, Oregon, 97223, United States

  • Clinical Research Site

    Hershey, Pennsylvania, 17033, United States

  • Clinical Research Site

    Pittsburgh, Pennsylvania, 15213, United States

  • Clinical Research Site

    Sugarloaf, Pennsylvania, 18249, United States

  • Clinical Research Site

    Thompson's Station, Tennessee, 37179, United States

  • Clinical Research Site

    Arlington, Texas, 76011, United States

  • Clinical Research Site

    Frisco, Texas, 75034, United States

  • Clinical Research Site

    Pflugerville, Texas, 78660, United States

  • Clinical Research Site

    San Antonio, Texas, 78218, United States

  • Clinical Research Site

    The Woodlands, Texas, 77380, United States

  • Clinical Research Site

    Webster, Texas, 77598, United States

  • Clinical Research Site

    Springville, Utah, 84663, United States

  • Clinical Research Site

    West Jordan, Utah, 84088, United States

  • Clinical Research Site

    Charlottesville, Virginia, 22908, United States

  • Clinical Research Site

    Edmonton, Alberta, T6G1C3, Canada

  • Clinical Research Site

    Edmonton, Alberta, T6H4J8, Canada

  • Clinical Research Site

    Winnipeg, Manitoba, R3M3Z4, Canada

  • Clinical Research Site

    North Bay, Ontario, P1B 3Z7, Canada

  • Clinical Research Site

    Peterborough, Ontario, K9J5K2, Canada

  • Clinical Research Site

    Toronto, Ontario, M2N3A6, Canada

  • Clinical Research Site

    Toronto, Ontario, M4W2N4, Canada

  • Clinical Research Site

    Toronto, Ontario, M5A3R6, Canada

  • Clinical Research Site

    Waterloo, Ontario, N2J1C4, Canada

  • Clinical Research Site

    Saskatoon, Saskatchewan, S7K2C1, Canada

  • Clinical Research Site

    Dijon, Bourgogne-Franche-Comté, 21000, France

  • Clinical Research Site

    Montpellier, Occitanie, 34090, France

  • Clinical Research Site

    Nantes, Pays de la Loire Region, 44000, France

  • Clinical Research Site

    Toulon, 83000, France

  • Clinical Research Site

    Darmstadt, Hesse, 64283, Germany

  • Clinical Research Site

    Bad Bentheim, Lower Saxony, 48455, Germany

  • Clinical Research Site

    Mainz, Rhineland-Palatinate, 55128, Germany

  • Clinical Research Site

    Leipzig, Saxony, 04103, Germany

  • Clinical Research Site

    Kiel, Schleswig-Holstein, 24148, Germany

  • Clinical Research Site

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Clinical Research Site

    Zalaegerszeg, Zala County, 8900, Hungary

  • Clinical Research Site

    Budapest, 1036, Hungary

  • Clinical Research Site

    Fukuoka, Fukoka Prefecture, 814-0180, Japan

  • Clinical Research Site

    Kitakyushu, Fukuoka, 807-8555, Japan

  • Clinical Research Site

    Obihiro, Hokkaido Prefecture, 080-0013, Japan

  • Clinical Research Site

    Sapporo, Hokkaido Prefecture, 060-0063, Japan

  • Clinical Research Site

    Kawasaki, Kanagawa, 216-8511, Japan

  • Clinical Research Site

    Yokohama, Kanagawa, 236-0004, Japan

  • Clinical Research Site

    Kyoto, Kyoto, 602-8566, Japan

  • Clinical Research Site

    Osaka, Osaka, 589-8511, Japan

  • Clinical Research Site

    Shinjuku-Ku, Tokyo, 160-0023, Japan

  • Clinical Research Site

    tabashi City, Tokyo, 173-8610, Japan

  • Clinical Research Site

    Nishinomiya, 663-8186, Japan

  • Clinical Research Site

    Krakow, Lesser Poland Voivodeship, 30-001, Poland

  • Clinical Research Site

    Krakow, Lesser Poland Voivodeship, 90-436, Poland

  • Clinical Research Site

    Wroclaw, Lower Silesian Voivodeship, 50-566, Poland

  • Clinical Research Site

    Wroclaw, Lower Silesian Voivodeship, 51-318, Poland

  • Clinical Research Site

    Lublin, Lublin Voivodeship, 20-573, Poland

  • Clinical Research Site

    Katowice, Silesian Voivodeship, 40-611, Poland

  • Clinical Research Site

    Ożarowice, Silesian Voivodeship, 42-624, Poland

  • Clinical Research Site

    Sosnowiec, Silesian Voivodeship, 41-218, Poland

  • Clinical Research Site

    Lodz, Łódź Voivodeship, 90-265, Poland

  • Clinical Research Site

    Seville, Andalusia, 41009, Spain

  • Clinical Research Site

    Palma de Mallorca, Balearic Islands, 07120, Spain

  • Clinical Research Site

    Badalona, Catalonia, 08916, Spain

  • Clinical Research Site

    Barcelona, Catalonia, 08041, Spain

  • Clinical Research Site

    Manises, Valencia, 46940, Spain

  • Clinical Research Site

    Madrid, 28031, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.